Mandadi Tilak

EVP, Chief Exp & Tech Officer

Mandadi Tilak has filed 4 SEC Form 4 filings (5 transaction rows) across 1 company, with disclosures dating back to 2025. 3 of those filings fall inside the rolling window. Most recent filing: May 11, 2026.

On the most recent filing, Mandadi Tilak is listed as EVP, Chief Exp & Tech Officer at CVS HEALTH Corp. Inside the rolling window, Mandadi Tilak reported no open-market purchases and 1 open-market sale totaling $6.2M in CVS.

Companies traded

Other insiders at CVS

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$6.2M

reported sales (SEC code S)

Companies

1

in the rolling window

Source
CVSSale$6.2MMay 11SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Mandadi Tilak made?

Mandadi Tilak has filed 4 SEC Form 4 filings (5 transaction rows) across 1 company since 2025.

Which companies does Mandadi Tilak trade?

Mandadi Tilak has filed SEC Form 4 disclosures for 1 company, including CVS.

When was Mandadi Tilak's most recent SEC Form 4 filing?

Mandadi Tilak's most recent SEC Form 4 filing on Tracefour is dated May 11, 2026.

What is Mandadi Tilak's job title?

On the most recent SEC Form 4 filings tracked by Tracefour, Mandadi Tilak is listed as EVP, Chief Exp & Tech Officer.

What is Mandadi Tilak's total buy and sell value in the current window?

Inside the rolling retention window, Mandadi Tilak bought $0 and sold $6.2M based on SEC Form 4 filings.

What was Mandadi Tilak's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 69,551 CVS shares on 2026-05-08, worth $6.2M, per SEC Form 4 filings.